Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Berlin - Delayed Quote EUR

Astellas Pharma Inc (YPH.BE)

Compare
9.29
-0.19
(-2.01%)
At close: February 28 at 6:46:14 PM GMT+1
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
1,603,672,000
1,603,672,000
1,518,619,000
1,296,163,000
1,249,528,000
Cost of Revenue
292,485,000
292,485,000
288,353,000
253,009,000
246,063,000
Gross Profit
1,311,187,000
1,311,187,000
1,230,266,000
1,043,154,000
1,003,465,000
Operating Expense
1,292,240,000
1,292,240,000
1,098,709,000
912,191,000
867,892,000
Operating Income
18,947,000
18,947,000
131,557,000
130,963,000
135,573,000
Net Non Operating Interest Income Expense
-550,000
-550,000
-669,000
1,200,000
9,273,000
Pretax Income
24,969,000
24,969,000
132,361,000
156,886,000
145,324,000
Tax Provision
7,924,000
7,924,000
33,647,000
32,800,000
24,734,000
Net Income Common Stockholders
17,045,000
17,045,000
98,714,000
124,086,000
120,589,000
Diluted NI Available to Com Stockholders
17,045,000
17,045,000
98,714,000
124,086,000
120,589,000
Basic EPS
9.51
9.51
54.24
67.08
64.93
Diluted EPS
9.47
9.47
54.09
67.05
64.90
Basic Average Shares
1,793,276.62
1,793,276.62
1,820,019
1,849,713
1,857,125
Diluted Average Shares
1,799,660
1,799,660
1,825,061
1,850,602
1,858,193
Total Operating Income as Reported
25,518,000
25,518,000
133,029,000
155,686,000
136,051,000
Total Expenses
1,584,725,000
1,584,725,000
1,387,062,000
1,165,200,000
1,113,955,000
Net Income from Continuing & Discontinued Operation
17,045,000
17,045,000
98,714,000
124,086,000
120,589,000
Normalized Income
10,399,436.50
10,399,436.50
98,555,891.74
104,916,906
120,589,000
Interest Income
11,455,000
11,455,000
8,110,000
6,149,000
11,608,000
Interest Expense
12,005,000
12,005,000
8,779,000
4,949,000
2,335,000
Net Interest Income
-550,000
-550,000
-669,000
1,200,000
9,273,000
EBIT
36,974,000
36,974,000
141,140,000
161,835,000
147,659,000
EBITDA
194,814,000
194,814,000
246,878,000
241,519,000
220,311,000
Reconciled Cost of Revenue
292,485,000
292,485,000
288,353,000
253,009,000
246,063,000
Reconciled Depreciation
157,840,000
157,840,000
105,738,000
79,684,000
72,652,000
Net Income from Continuing Operation Net Minority Interest
17,045,000
17,045,000
98,714,000
124,086,000
120,589,000
Total Unusual Items Excluding Goodwill
9,735,000
9,735,000
212,000
24,234,000
--
Total Unusual Items
9,735,000
9,735,000
212,000
24,234,000
--
Normalized EBITDA
185,079,000
185,079,000
246,666,000
217,285,000
220,311,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
3,089,436.50
3,089,436.50
53,891.74
5,064,906
--
3/31/2021 - 12/13/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BRM.MU Bristol-Myers Squibb Co
56.83
+3.29%
 
ABBV34.SA AbbVie Inc.
76.22
+2.32%
 
OZTA.SG Grifols SA
10.43
+0.29%
 
BRM.F Bristol-Myers Squibb Company
55.92
-0.85%
 
1643.HK MODERN CHI MED
0.390
-1.27%
 
COPNz.XC
 
NOVNEE.SW Novartis AG
98.06
+0.40%
 
BAYN.SG Bayer AG
22.66
+0.22%
 
MRK.BA Merck & Co., Inc.
22,375.00
+1.94%
 
4AB.F AbbVie Inc.
197.68
+2.16%